Immatics NV (IMTX)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treat...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Immatics NV Analyst Rating
View moreForecast & Rating
Aug 25, 2026Price forecast
$17.6399.92%
Forecast & RatingStrong buy
8analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Sep 3 at 10:12 AM
Market Signals Point to Defensive Yield and Niche Growth Amid Macro Volatility
- Market Beat · Aug 28 at 03:20 PM
Immatics (NASDAQ:IMTX) Shares Up 5.3% on Insider Buying Activity
- PUBT · Aug 27 at 08:00 PM
Perceptive Life Sciences Master Fund acquires USD 7.5 million in Immatics shares
- benzinga_article · Aug 25 at 12:42 PM
Immatics shares are trading higher after the company announced a $150 million offering.
- PUBT · Aug 25 at 11:00 AM
Immatics prices $150 million follow-on offering at $8.69 per share
